Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events ...
As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...
By a News Reporter-Staff News Editor at Disease Prevention Daily-- A new study on Drugs and Therapies- Kinase Inhibitors is now available. Financial supporters for this research include Taiju Life ...
Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...
MedPage Today on MSN
Overcoming CDK4/6 inhibitor resistance in HR-positive/HER2-negative breast cancer
The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...
Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...
AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results